PEDIATRICS Vol. 92 No. 4 October 1993, pp. A48
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Figueroa, M. L.
Right arrow Articles by L., J. F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Figueroa, M. L.
Right arrow Articles by L., J. F.

A LESS COSTLY REGIMEN OF ALGLUCERASE TO TREAT GAUCHER'S DISEASE

Michael L. Figueroa MD, Barry E. Rosenbloom MD, Andrea C. Kay MD, and J. F. L. MD

Alglucerase (Ceredase) provides effective enzyme-replacement treatment for patients with Gaucher's disease, but at the usually recommended dose of 60 U per kilogram of body weight every two weeks (130 U per kilogram per month), it costs $382,200 per year for a 70-kg patient. Theoretical considerations suggest that more frequent administration would be more efficient...

The treatment of Gaucher's disease with smaller total doses of alglucerase given more frequently yields satisfactory results. A dose of 2.3 U per kilogram three times weekly yields major financial benefits with no sacrifice of therapeutic effect. Even taking into account the ancillary costs of more frequent administration, this method of administering alglucerase reduces the annual cost of the drug for a 70-kg patient to about $100,000. (N Engl J Med. 1992;327:1632-1636.)